5,000 kidney patients enrolled in landmark registry study

NCT ID NCT06117852

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is creating a registry of 5,000 adults with chronic kidney disease (CKD) to collect information on their health, treatments, and outcomes. Researchers aim to understand how the disease progresses, identify risk factors, and see how well current treatments match guidelines. No new treatments are being tested—this is purely an observation and data-gathering effort.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could help doctors better predict how chronic kidney disease will progress and improve treatment guidelines.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help participants. Results may take years and might not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Research Site

Baotou, China
Research Site

Beijing, China
Research Site

Changsha, China
Research Site

Changzhou, China
Research Site

Chengdu, China
Research Site

Chongqing, China
Research Site

Dongguan, China
Research Site

Guangzhou, China
Research Site

Haikou, China
Research Site

Hefei, China
Research Site

Hengyang, China
Research Site

Huaian, China
Research Site

Jilin City, China
Research Site

Jining, China
Research Site

Nanchang, China
Research Site

Nanjing, China
Research Site

Nanning, China
Research Site

Ningbo, China
Research Site

Panjin, China
Research Site

Pingxiang, China
Research Site

Shanghai, China
Research Site

Shantou, China
Research Site

Shenzhen, China
Research Site

Taizhou, China
Research Site

Wenzhou, China
Research Site

Wuhan, China
Research Site

Wuxi, China
Research Site

Xiamen, China
Research Site

Xianyang, China
Research Site

Yantai, China
Research Site

Yibin, China
Research Site

Zhongshan, China
Research Site

Zhuzhou, China
Research Site

Zigong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.